Is Repare Therapeutics Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Repare Therapeutics Inc (RPTX) is currently classified as NOT HALAL as of November 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Repare Therapeutics Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Repare Therapeutics Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Repare Therapeutics Inc?

Muslim investors may consider investing in Repare Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Repare Therapeutics Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Repare Therapeutics Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Repare Therapeutics Inc updated?

The Shariah compliance status of Repare Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Repare Therapeutics Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Repare Therapeutics Inc?

You can check the latest Shariah compliance status of Repare Therapeutics Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

RPTX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: November 21, 2025

Report Source: 2025 3rd Quarter Report

Repare Therapeutics Inc. Stock Analysis RPTX

United States Health Care Micro Cap Report: Q3, 2025

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company is headquartered in St-Laurent, Quebec and currently employs 129 full-time employees. The company went IPO on 2020-06-19. The firm utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.

Key Statistics of Repare Therapeutics Inc (RPTX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$2.62$2.65

Today's Open

$2.64

Volume

1.22M

P/E Ratio (TTM)

52 Week Range

$0.89$2.66

Market Cap

110.36M

Avg. Volume

1.18M

Dividend Yield

Financial Metrics & Statements of Repare Therapeutics Inc (RPTX)

FAQ's for Repare Therapeutics Inc (RPTX)

According to Musaffa’s Shariah screening methodology, Repare Therapeutics Inc (RPTX) is currently classified as NOT HALAL as of November 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.